chufangao/CTO huggingface dataset:
Clinical trial NCT03690141: An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer
Official title: A Phase 2 Non-randomized Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)
Sponsor: Effector Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Terminated early due to a lack of efficacy.
Enrollment: 16.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-11-27
Primary completion date: 2020-04-27
Completion date: 2020-04-27
Plan to share individual participant data: NO
Clinical trial NCT04604678: Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19
Official title: Pilot Study Into the Use of Metformin and Low Dose Naltrexone (LDN) for Patients With Coronavirus Disease 2019 (COVID-19) - Assessment of Short and Long Term Effects
Sponsor: AgelessRx (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Unable to recruit participants due to restrictive inclusion/exclusion criteria. Will update protocol with IRB \& begin anew after approval.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-28
Primary completion date: 2021-08-31
Completion date: 2021-10-31
Plan to share individual participant data: NO
Clinical trial NCT03192995: Treatment With Lorcaserin for Cocaine Use: The TLC Study
Official title: Treatment With Lorcaserin for Cocaine Use: The TLC Study
Acronym: TLC
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: FDA alert regarding study drug safety
Enrollment: 22.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-01
Primary completion date: 2020-02-28
Completion date: 2020-06-30
Baseline population: Treatment and control assignments
Limitations and caveats: The study was terminated early by the FDA due to the publication of a long-term safety study that showed an increase risk for cancer by the lorcaserin arm.
Plan to share individual participant data: NO
Clinical trial NCT03503513: Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury
Official title: The Effect of Gentamicin Intravesical Installations on Decreasing Urinary Tract Infections in Patients With Neurogenic Bladder After Spinal Cord Injury: A Clinical Trial
Sponsor: University of Michigan (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-08-24
Primary completion date: 2023-09-08
Completion date: 2023-09-30
Baseline population: Baseline data is provided for all participants who started treatment
Plan to share individual participant data: NO
Clinical trial NCT01058902: The Effect Of Aspirin On Survival in Lung Cancer
Official title: The Effect Of Aspirin On Survival Following Potentially Curative Resection Of Non Small Cell Carcinoma Of The Lung The Big A Trial
Sponsor: Liverpool Heart and Chest Hospital NHS Foundation Trust (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: failed to achive funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2010-08-31
Primary completion date: 2015-08-31
Completion date: 2020-08-31
Clinical trial NCT04672564: Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
Official title: A Phase 3, Randomized, Multicenter, Placebo-controlled, Double-blind Clinical Study of the Safety and Efficacy of Carrimycin for Treatment of Severe COVID-19 in Hospitalized Patients
Sponsor: Shenyang Tonglian Group CO., Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: sponsor strategy change
Enrollment: 93.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-30
Primary completion date: 2022-03-24
Completion date: 2022-05-09
Clinical trial NCT03295552: Decitabine Plus Carboplatin in the Treatment of Metastatic TNBC
Official title: Decitabine Plus Carboplatin in the Treatment of Metastatic Triple Negative Breast Cancer
Acronym: DETECT
Sponsor: Shanghai Jiao Tong University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow enrollment.
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-11-15
Primary completion date: 2021-06-01
Completion date: 2021-06-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04513704: A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times
Official title: Oral Semaglutide Pharmacokinetics in Healthy Subjects, Effect of Dosing Schedules
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 156.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-08-28
Primary completion date: 2021-04-20
Completion date: 2021-05-26
Plan to share individual participant data: YES
IPD sharing description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Clinical trial NCT04956042: Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Official title: A Phase 1B/2A, Open-label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Fosciclopirox Alone and In Combination With Cytarabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Sponsor: CicloMed LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Discontinued
Enrollment: 18.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-27
Primary completion date: 2023-12-31
Completion date: 2023-12-31
Clinical trial NCT02366728: DC Migration Study for Newly-Diagnosed GBM
Official title: Evaluation of Overcoming Limited Migration and Enhancing Cytomegalovirus-specific Dendritic Cell Vaccines With Adjuvant TEtanus Pre-conditioning in Patients With Newly-diagnosed Glioblastoma
Acronym: ELEVATE
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 64.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-10-12
Primary completion date: 2020-10-31
Completion date: 2020-10-31
Baseline population: Participants who received at least one ppp65 vaccine.
Clinical trial NCT05237284: Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Official title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR443820 in Adult Participants With Amyotrophic Lateral Sclerosis, Followed by an Open-label Extension
Acronym: HIMALAYA
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated as its Part A did not meet the primary endpoint.
Enrollment: 305.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-04-13
Primary completion date: 2024-03-07
Completion date: 2024-03-07
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT02653300: A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)
Official title: An Open-Label Pilot Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Potential of Oral Insulin to Reduce Liver Fat Content and Fibrosis in Patients With Nonalcolholic Steatohepatitis (NASH)
Sponsor: Oramed, Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-09-20
Primary completion date: 2020-03-01
Completion date: 2020-04-01
Limitations and caveats: This is a pilot study with ten subjects enrolled, and eight subjects analyzed.
Plan to share individual participant data: NO
Clinical trial NCT06037408: The Effect of N115 on Coughing in IPF Patients
Official title: The Effect of Sodium Pyruvate Nasal Spray on Coughing in Patients With Idiopathic Pulmonary Fibrosis
Sponsor: Cellular Sciences, inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-08-15
Primary completion date: 2024-05-16
Completion date: 2024-05-20
Plan to share individual participant data: NO
Clinical trial NCT06032936: BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations
Official title: An Open-label, Non-randomized, Multi-cohort, Multi-center Phase Ia/Ib Study Evaluating the Efficacy and Safety of BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations
Sponsor: LianBio LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business reason
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-07-27
Primary completion date: 2024-03-29
Completion date: 2024-03-29
Clinical trial NCT04656262: Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients
Official title: The METROPHOLYS Study Metronomic Cyclophosphamide vs Doxorubicin in Elderly Patients With Advanced Soft Tissue Sarcomas Randomized, Controlled Open Label Clinical Trial
Acronym: METROPHOLYS
Sponsor: Istituto Oncologico Veneto IRCCS (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: enrollment too slow to reach the target in a reasonable time frame
Enrollment: 79.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-10
Primary completion date: 2024-05-23
Completion date: 2024-05-23
Clinical trial NCT04507061: Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels.
Official title: A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Individually Titrated Oral Doses of Runcaciguat in Subjects With Clinical Diagnosis of Chronic Kidney Disease With Diabetes and/or Hypertension and at Least One Cardiovascular Comorbidity
Acronym: CONCORD
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 243.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-01
Primary completion date: 2022-03-08
Completion date: 2022-04-05
Plan to share individual participant data: UNDECIDED
IPD sharing description: Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access.~As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.~Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Clinical trial NCT03952806: Study of BHV-3241 in Participants With Multiple System Atrophy
Official title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study)
Acronym: M-STAR
Sponsor: Biohaven Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 421.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-29
Primary completion date: 2021-07-29
Completion date: 2022-06-30
Baseline population: Treated participants included enrolled participants who received at least 1 dose of blinded study therapy (verdiperstat or placebo).
Clinical trial NCT03879811: Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer
Official title: Phase II Study of Temozolomide and Nivolumab in MMR-Proficient Colorectal Cancer (CA209-8JN)
Sponsor: Memorial Sloan Kettering Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-03-13
Primary completion date: 2021-03-31
Completion date: 2021-03-31
Plan to share individual participant data: YES
IPD sharing description: Here is the final approved MSK data sharing statement for posting on any trial opened 1/1/19 or later -~• Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Clinical trial NCT02953366: Efficacy and Safety of the Mometasone Nasal Gel in the Treatment of Persistent Allergic Rhinitis
Official title: Phase III, National, Multicenter, Randomized, Single-blind, Non-inferiority to Compare the Efficacy of Mometasone Nasal Gel Compared to Mometasone Nasal Spray in the Treatment of Persistent or Intermittent Allergic Rhinitis in Childrens
Sponsor: EMS (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Sponsor decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-31
Primary completion date: 2019-12-31
Completion date: 2020-05-31
Clinical trial NCT04352166: Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder
Official title: Randomized Controlled Trial of Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder Patients Using Fentanyl
Sponsor: New York State Psychiatric Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: U.S. Department of Health and Human Services OHRP issued an FWA restriction on NYSPI research that included a pause of human subjects research as of June 23, 2023. This study will resume recruitment after OHRP has approved the resumption of research.
Enrollment: 40.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2020-12-15
Primary completion date: 2024-12-31
Completion date: 2024-12-31
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie the results published in this report (after de-identification) (text, tables, figures)
IPD time frame: beginning twelve months and ending 5 years after article publication
IPD access criteria: to researcher who provides a methodologically sound proposal to achieve aims in approved proposal
Clinical trial NCT03817034: Multimodal Analgesia for the Reduction of Postoperative Opioid Consumption
Official title: Multimodal Analgesia for the Reduction of Postoperative Opioid Consumption
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: We decided to close this study and come up with a new study design.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-03-11
Primary completion date: 2021-03-11
Completion date: 2021-03-11
Clinical trial NCT04356352: Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain
Official title: A Comparison of Lidocaine, Esmolol, and Placebo Without Use of a Tourniquet for Relieving Pain From Intravenous Administration of Propofol
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: feasibility of enrollment
Enrollment: 33.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-09-09
Primary completion date: 2023-08-25
Completion date: 2023-08-25
Clinical trial NCT03430063: A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer
Official title: A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer
Sponsor: Regeneron Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Business decision
Enrollment: 28.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-05-29
Primary completion date: 2021-10-27
Completion date: 2021-10-27
Baseline population: Safety analysis set (SAF) included all randomized participants who received any study drug; it is based on the treatment received (as treated).
Limitations and caveats: All participants' tumors had PD-L1 expression levels of \<50% at baseline. Therefore, the results do not present efficacy for participants with PD-L1 expression levels of ≥50% of tumor cells versus all participants.
Clinical trial NCT03002519: Safety Evaluation of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation
Official title: A Phase I Open-label Dose-escalation Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation
Sponsor: Pluristem Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 21.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-02-08
Primary completion date: 2021-09-30
Completion date: 2021-10-30
Clinical trial NCT03321734: Intermittent Hypoxia and Caffeine in Infants Born Preterm
Official title: Intermittent Hypoxia and Caffeine in Infants Born Preterm (ICAF)
Acronym: ICAF
Sponsor: Children's National Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 170.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-18
Primary completion date: 2023-06-01
Completion date: 2023-06-01
Plan to share individual participant data: YES
IPD sharing description: The Executive Committee will be responsible for developing publication procedures and resolving authorship issues.~This study will be conducted in accordance with the National Institutes of Health (NIH) Public Access Policy, ensuring that the public has access to the published results of NIH funded research. Scientists are required to submit final peer-reviewed journal manuscripts that arise from NIH funds to PubMed Central upon acceptance for publication. This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH-Funded Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. This trial will be registered at, and results from, submitted to ClinicalTrials.gov. Every attempt will be made to publish results in peer-reviewed journals. Data may be requested from other researchers starting 6 months after the completion of the primary endpoint by contacting the DCC(data collection center).
IPD time frame: Starting 6 months after publication
IPD access criteria: De-identified patient data will be made available to other investigators at their request providing written required IRB (institutional review board) approval in obtained.
Clinical trial NCT04635683: Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Official title: A Phase I Trial of Lenalidomide, Umbralisib and Ublituximab in Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Sponsor: Ohio State University Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Investigational Drug removed from the market
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-09-30
Primary completion date: 2023-12-31
Completion date: 2024-12-31
Plan to share individual participant data: NO
Clinical trial NCT04637698: OH2 Oncolytic Viral Therapy in Pancreatic Cancer
Official title: Phase Ib/II Study of OH2 Injection, an Oncolytic Type 2 Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor, in Pancreatic Cancer
Sponsor: Binhui Biopharmaceutical Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Strategy adjustment
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-02-02
Primary completion date: 2023-05-04
Completion date: 2023-05-04
Clinical trial NCT03249714: Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab
Official title: A 24-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Ofatumumab in Patients With Relapsing Multiple Sclerosis Followed by an Extended Treatment of at Least 24 Weeks With Open-label Ofatumumab
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 64.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-15
Primary completion date: 2019-12-26
Completion date: 2020-07-29
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.
Clinical trial NCT03954041: A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion
Official title: A Multicenter, Double-Blind, Multidose, Placebo-Controlled, Randomized, Parallel-Group, Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 for Patients With Brain Contusion
Acronym: ASTRAL
Sponsor: Remedy Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Early completed due to strategic considerations, not for efficacy or safety reasons.
Enrollment: 92.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-10-06
Primary completion date: 2023-06-27
Completion date: 2023-06-27
Baseline population: All dosed population included all the randomized participants who received any study drug (BIIB093 or a placebo).
Limitations and caveats: Early termination of trial due to strategic considerations, not for efficacy or safety reasons.
Plan to share individual participant data: YES
IPD sharing description: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/